Sign In
TLIS.US
id: 1330

Talis Biomedical (TLIS) Investor Settlement

Late claims are being considered for compensation, subject to approval.
N.D. California
Court
3:22-cv-00105
Case number
02/11/2021
Class period Start
08/11/2021
Class period End
08/21/2024
Claim deadline
Talis Biomedical reached a settlement with $TLIS investors to resolve claims that it misled them about delays in approval and launch of the Talis One COVID-19 test.
Case Status
Accepting Late Claims
Alleged Offence
Mismanagement, 
Misleading Statements, 
Omissions
Suspected Party
Directors, 
Management, 
Research Entity
Security Type
Stocks
Trade Direction
Long
Payout per Share
2.05
Filing date
01/13/2023
Plaintiffs
John Modrak
Attorneys
Bleichmar Fonti & Auld LLP (New York, NY), Pomerantz LLP (Los Angeles, CA), The Schall Law Firm (Los Angeles, CA)
Defendants
Brian Coe, J. Roger Moody, Jr., Felix Baker
Judge
Hon. Susan Illston
Administrator
A.B. Data Ltd
Exclusion deadline
08/20/2024
Attorney fee
$10,900,000
Class wide damages
$201,390,300
Trades matching type
FIFO
+$32,500,000
Cash Settlement Amount

Frequently Asked Questions

When will you be able to apply for the payment?
Do I have to sell securities to be eligible?
How long does the payout process take?
What is 11thestate?

Talis Biomedical Corp

Talis Biomedical Corporation operates as a molecular diagnostic company, focusing on developing medical devices for infectious diseases and other conditions at the point of care in the United State...

    Ticker
    TLIS.US
    ISIN
    US87424L1089
    CIK
    1584751
    Sector
    Healthcare
    Industry
    Medical Devices
    Country
    USA
    Address
    1375 West Fulton Market, Chicago, IL, United States, 60607